NDATOPICALPATCH
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZTLIDO (lidocaine) by PharmaIN is clinical pharmacology mechanism of action: lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 2018.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZTLIDO is a topical lidocaine 5% patch approved in 2018 for localized pain relief via topical anesthesia. It works by stabilizing neuronal membranes to inhibit ionic fluxes required for pain signal initiation and conduction, with onset of action within 3–5 minutes. The patch delivers amide-class local anesthetic therapy for patients seeking non-systemic pain management.
$0.051BPart D
Peak4.5 years to LOEZTLIDO is in peak commercial phase with $51M in Part D spending and 78,603 claims annually, indicating a stable and established revenue base supporting a mature brand team.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of action: Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Onset of anesthesia: Lidocaine Ointment 5% effects local, topical anesthesia. The…
Worked on ZTLIDO at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.